IL-31 plays a role in many inflammatory skin diseases, including AD and PN.1-3 IL-31 bridges the peripheral nervous system and immune system and targets structural skin cells, driving itch, inflammation, and skin abnormalities.1  

3 overlapping circles, labeled as follows: AD, IL-31, and PN.

IL-31 is a central mediator of neuroimmune skin dysfunction

The center of neuroimmune skin dysfunction¹

Ready to dive deeper?

Watch these videos for a closer look at the role of IL-31 in AD and PN.

The burden of disease in AD

The signs and symptoms of AD can significantly disrupt patients’ daily lives.4,5

What is PN?

PN is characterized by disfiguring
nodules and intractable itch.3

Useful resources

The images in this material are not of actual patients with AD or PN. They were created based on informed Galderma insights. AD and PN can manifest in individuals differently. 

1. ​Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med (Lausanne). 2021;8:639097. doi:10.3389/fmed.2021.639097 2. Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J. Interleukin-31: the "itchy" cytokine in inflammation and therapy. Allergy. 2021;76(10):2982-2997. doi:10.1111/all.14791 3. Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2021;14(1):67-77. doi:10.1080/17512433.2021.1852080 4. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360. doi:10.1016/S0140-6736(20)31286-1 5. McCleary KK. More than skin deep: understanding the lived experience of eczema. March 18, 2020. Accessed December 15, 2021. http://www.morethanskindeep-eczema.org/report.html


Interested in learning more?
Sign up for more information about IL-31, atopic dermatitis, and prurigo nodularis by submitting the form below.
By completing and submitting this form, you grant permission and agree to allow Galderma Laboratories, L.P. and its affiliates (“Galderma”) to collect the information you provide so that Galderma may market or advertise to you across multiple channels. For additional information regarding how Galderma handles your information, please see our privacy policy.

Please note, by submitting you agree that any personal information provided by you with your entry may be held and used by Galderma Laboratories, L.P. or its affiliates and agents to administer your request for information about IL-31, atopic dermatitis, and prurigo nodularis.